These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35216318)

  • 21. Reduced CD127 expression on peripheral CD4+ T cells impairs immunological recovery in course of suppressive highly active antiretroviral therapy.
    Bai F; Bellistrì GM; Tincati C; Savoldi A; Pandolfo A; Bini T; Carpani G; Sinigaglia E; Marchetti G; d'Arminio Monforte A
    AIDS; 2010 Oct; 24(16):2590-3. PubMed ID: 20935556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief Report: Polymorphisms in TNF-α/TNFR1 Pathway Genes Are Associated With CD4+ T-Cell Recovery in HIV-1-Infected Individuals on Antiretroviral Therapy.
    Celerino da Silva R; Alves NMP; Gondim Silva ML; Agrelli A; Coelho AVC; Guimarães RL; Arraes LC; Crovella S; Brandão LAC
    J Acquir Immune Defic Syndr; 2021 Nov; 88(3):322-327. PubMed ID: 34267056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Finlayson R; Zaunders J; Smith D; Cooper DA
    AIDS; 2002 Feb; 16(3):359-67. PubMed ID: 11834947
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
    Negredo E; Massanella M; Puig J; Pérez-Alvarez N; Gallego-Escuredo JM; Villarroya J; Villarroya F; Moltó J; Santos JR; Clotet B; Blanco J
    Clin Infect Dis; 2010 May; 50(9):1300-8. PubMed ID: 20367229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Transcriptional Analysis Identified Characteristic Genes and Patterns in HIV-Infected Immunological Non-Responders.
    Liu X; Lin L; Lu L; Li X; Han Y; Qiu Z; Li X; Li Y; Song X; Cao W; Li T
    Front Immunol; 2022; 13():807890. PubMed ID: 35154126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of suboptimal CD4
    Handoko R; Colby DJ; Kroon E; Sacdalan C; de Souza M; Pinyakorn S; Prueksakaew P; Munkong C; Ubolyam S; Akapirat S; Chiarella J; Krebs S; Sereti I; Valcour V; Paul R; Michael NL; Phanuphak N; Ananworanich J; Spudich S;
    J Int AIDS Soc; 2020 Sep; 23(9):e25585. PubMed ID: 32949118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy.
    Weiss L; Burgard M; Cahen YD; Chaix ML; Laureillard D; Gilquin J; Piketty C; Viard JP; Kazatchkine MD; Girard PM; Rouzioux C
    HIV Med; 2002 Jan; 3(1):12-20. PubMed ID: 12059946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL18 gene polymorphism and its influence on CD4+ T-cell recovery in HIV-positive patients receiving antiretroviral therapy.
    Andrade-Santos JL; Carvalho-Silva WHV; Coelho AVC; Souto FO; Crovella S; Brandão LAC; Guimarães RL
    Infect Genet Evol; 2019 Nov; 75():103997. PubMed ID: 31401307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients.
    Al-Harthi L; Voris J; Patterson BK; Becker S; Eron J; Smith KY; D'Amico R; Mildvan D; Snidow J; Pobiner B; Yau L; Landay A
    HIV Med; 2004 Jan; 5(1):55-65. PubMed ID: 14731171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
    Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
    HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.
    Piconi S; Trabattoni D; Gori A; Parisotto S; Magni C; Meraviglia P; Bandera A; Capetti A; Rizzardini G; Clerici M
    AIDS; 2010 Aug; 24(13):1991-2000. PubMed ID: 20651586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant responses to cART in HIV-1 patients in the era of high potency antiretroviral drugs: clinical evaluation, classification, management prospects.
    Cenderello G; De Maria A
    Expert Rev Anti Infect Ther; 2016; 14(1):29-40. PubMed ID: 26513236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implications of accumulation of clonally expanded and senescent CD4
    Yang X; Zhen C; Huang H; Jiao Y; Fan X; Zhang C; Song J; Wang S; Zhou C; Yang X; Yuan J; Zhang J; Xu R; Wang FS
    Emerg Microbes Infect; 2024 Dec; 13(1):2396868. PubMed ID: 39239709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects.
    Rosado-Sánchez I; Herrero-Fernández I; Álvarez-Ríos AI; Genebat M; Abad-Carrillo MA; Ruiz-Mateos E; Pulido F; González-García J; Montero M; Bernal-Morell E; Vidal F; Leal M; Pacheco YM
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.